In today’s recent session, 1.94 million shares of the Moderna Inc (NASDAQ:MRNA) have been traded, and its beta is 1.62. Most recently the company’s share price was $38.28, and it changed around -$1.23 or -3.11% from the last close, which brings the market valuation of the company to $14.73B. MRNA at last check was trading at a discount to its 52-week high of $170.47, offering almost -345.32% off that amount. The share price’s 52-week low was $35.80, which indicates that the recent value has risen by an impressive 6.48% since then. We note from Moderna Inc’s average daily trading volume that its 10-day average is 13.37 million shares, with the 3-month average coming to 6.29 million.

Moderna Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.57. If we narrow it down even further, the data shows that 2 out of 29 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 15 recommended MRNA as a Hold, whereas 7 deemed it a Buy, and 2 rated it as Underweight. Moderna Inc is expected to report earnings per share of -2.62 for the current quarter.

Moderna Inc (NASDAQ:MRNA) trade information

Instantly MRNA has been showing red trend so far today with a performance of -3.11% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 43.28 on recent trading dayincreased the stock’s daily price by 11.55%. The company’s shares are currently down -61.51% year-to-date, but still down -11.94% over the last five days. On the other hand, Moderna Inc (NASDAQ:MRNA) is -28.85% down in the 30-day period. We can see from the shorts that 34.38 million shares have been sold at a short interest cover period of 7.59 day(s).

The consensus price target as assigned by Wall Street analysts is $145, which translates to bulls needing to increase their stock price by 73.6% from its current value. Analyst projections state that MRNA is forecast to be at a low of $55 and a high of $304.

Moderna Inc (MRNA) estimates and forecasts

Moderna Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -73.36 percent over the past six months and at a 23.52% annual growth rate that is well above the industry average of 17.80%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will loss -592.80% in revenue this quarter, and will report an increase of 0.73% in the next quarter. The year-over-year growth rate is expected to be -51.71%, down from the previous year.

Consensus estimates provided by 12 financial analysts predict the company will bring in an average of 1.03B in revenue for the current quarter. 6 analysts expect Moderna Inc to make 235.09M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 2.81B and 167M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -63.50%. Forecasts for the next quarter put sales growth at 40.77%.

Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -20.02%.

MRNA Dividends

Moderna Inc’s next quarterly earnings report is expected to be released on 2025-Feb-20.

Moderna Inc (NASDAQ:MRNA)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 9.52% of Moderna Inc shares, and 71.62% of them are in the hands of institutional investors. The stock currently has a share float of 79.16%. Moderna Inc stock is held by 1216.0 institutions, with BAILLIE GIFFORD & CO being the largest institutional investor. By 2024-06-30, it held 11.3741% of the shares, which is about 43.45 million shares worth $5.16 billion.

VANGUARD GROUP INC, with 10.3568% or 39.56 million shares worth $4.7 billion as of 2024-06-30, holds the second largest percentage of outstanding shares.